Physician profile
Wesley Glenn Acker
NPI 1134178452
$10,003.59
in general payments reported to CMS, 2019-2025
60 companies · $1,870 in 2025
The $1,870 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,668 · 2020: $285 · 2021: $769 · 2022: $1,253 · 2023: $1,922 · 2024: $2,236 · 2025: $1,870.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,939 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,938.53 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,001.12 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $901.94 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $873.40 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $697.73 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $678.67 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $672.34 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbott Laboratories | $619.35 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $595.85 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $372.41 | 2019-2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $344.84 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.49 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $256.15 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Amarin Pharma, INC. | $192.40 | 2019-2022 | |
| Corcept Therapeutics | $191.13 | 2024-2025 | Korlym |
| Esperion Therapeutics, INC. | $150.51 | 2021 |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wesley Acker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.